Radiolife studies production of equipment for diagnosis of Covid-19 in Brazil

Radiolife studies production of equipment for diagnosis of Covid-19 in Brazil

Radiolife estuda produção de equipamento para diagnóstico de Covid-19 no Brasil

On Monday (28/12), the Scientific Committee and the Engineering Division of Radiolife discussed the possibility of producing nationally the Cubescan. This solution was developed by the company for Covid-19 diagnosis.

The device has several advantages that allow the startup to make the test available on a mass scale. The idea arose from the high demand for the equipment in Brazil. "We are still evaluating the tax burden and other taxes involved in manufacturing," said one of the owners of the company, Sergio Schirmer.

Currently, the production line is concentrated in California (United States), where Radiolife's headquarters are located. Therefore, the solution would reach Brazil through exports.

Since March 2020, Radiolife has been working on a solution that can establish a safe and rapid diagnosis of Covid-19. This decision was made after realizing the low success rate of rapid tests and the delay in the results of other types of tests. Based on radio frequency technology, the solution presents results in 10 seconds. In addition to speed, the processing does not require the use of reagents.


Radiolife is a startup based in Silicon Valley. Since March 2020, it turned its research and development sector to the creation of a solution for diagnosis of the new coronavirus. The company focuses on innovation and development of technologies to increase human longevity. It already had patented solutions for the health area, such as a technology for cancer diagnosis and treatment.

Questions? Comments? Concerns? Contact us for more information. We'll quickly get back to you with the information you need.